Abstract 840P
Background
This study aimed to obtain a deeper understanding of the molecular mechanisms underlying extranodal NK/T-cell lymphoma, nasal type (ENKTCL) by conducting Next-Generation Sequencing (NGS) of patients with ENKTCL.
Methods
This study included patients with ENKTCL who had complete tissue NGS results from two prior prospective studies. Group 1 comprised early-stage patients, while advanced-stage or relapsed patients were classified into Group 2. R language was used to visualize the mutation data.
Results
40 out of 98 patients with ENKTCL from two prospective clinical trials were included. Group 1 comprised 67.5% (n=27) of the patients, while group 2 accounted for 32.5% (n=13). Mutations in KLRC2 (29.6%), CIITA (25.9%), KLRC1 (25.9%), ITK (18.5%) were exclusively observed in group 1, with KLRC2 mutations occurring significantly more frequently in group 1 than group 2 (P = 0.037). KMT2D and TP53 exhibited the highest mutation rates and displayed different amino acid alterations in the two groups. The top KEGG pathway enriched by mutated genes was non-small cell lung cancer in group 1, and hepatitis B pathway in group 2. Patients with JAK3 wild-type exhibited remarkably improved PFS and OS rates than those with JAK3 mutations (P = 0.003, P = 0.033). Improved OS was also observed in patients with BCOR wild-type, although no significantly difference was found in PFS (P = 0.049, P = 0.172). Patients with PD-L1-positive expression had a significantly longer OS compared to those with PD-L1-negative expression (P = 0.037). Patients with PD-L1 expression < 50% were more likely to have BCOR mutations (41.7% vs. 0%, P = 0.012) and JAK3 gene mutations (33.3% vs. 0%, P = 0.033) than those with PD-L1 expression ≥ 50%.
Conclusions
The present study has, for the first time, explored disparities in mutation rates, mutation sites, and associated pathways among patients with early-stage versus advanced-stage/relapsed ENKTCL. JAK3 mutations, BCOR mutations, and PD-L1-negative expression were associated with poor prognosis of ENKTCL. Patients with PD-L1 expression < 50% were more likely to have BCOR mutations and JAK3 mutations than those with PD-L1 expression ≥50%.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
978P - Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)
Presenter: Claudia Fulgenzi
Session: Poster session 18
979P - Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ+BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
Presenter: Maria Elisa Reig Monzon
Session: Poster session 18
980P - Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma
Presenter: Young Mi Hong
Session: Poster session 18
981P - The response of portal vein tumoral thrombosis to moderately hypo-fractionated radiotherapy using intensity modulated radiotherapy
Presenter: Ahmad Abdel-Azeez
Session: Poster session 18
982P - Transarterial chemoembolization with idarubicin versus epirubicin for hepatocellular carcinoma: An interim analysis of a multicentre, randomized controlled phase III trial
Presenter: Zhewei Zhang
Session: Poster session 18
983P - Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis (Vp3/4) – the DurHope study
Presenter: Ming Zhao
Session: Poster session 18
984P - Comparative study of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma: A nationwide cohort study
Presenter: Jo Kook Lee
Session: Poster session 18
987P - Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
Presenter: Wonseok Kang
Session: Poster session 18
988P - Burden of primary liver cancer in the Middle East and North Africa Region from 1990 to 2019
Presenter: Ahmed Hafez Allam
Session: Poster session 18